Filing Details

Accession Number:
0001209191-22-003050
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-12 16:06:28
Reporting Period:
2022-01-10
Accepted Time:
2022-01-12 16:06:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1438533 Travere Therapeutics Inc. TVTX Pharmaceutical Preparations (2834) 262383102
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1698262 E. William Rote C/O Travere Therapeutics, Inc.
3611 Valley Centre Drive, Ste 300
San Diego CA 92130
Senior Vice President, R&D No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-10 5,000 $0.00 40,895 No 4 A Direct
Common Stock Disposition 2022-01-11 2,500 $27.40 38,395 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. On February 13, 2017, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 5,000 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million.
  2. The reporting person's Form 4 filed August 17, 2021 overstated the number of shares of the Issuer's common stock acquired by the reporting person on May 31, 2021 pursuant to an employee stock purchase program in the amount of 399 shares. The number of shares set forth in column 5 above has been adjusted to correct such overstatement and to include 563 shares of the Issuer's common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program.
  3. The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.